Cancer Clinical Trial
Official title:
Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation
Ayurvedic medicine has been practiced in for more than 2,500 years. Ashwagandha is one of the most widely utilized herbs in the system. It is thought to affect the endocrine, immune, nervous, and cardiopulmonary systems. This study is designed as a preliminary investigation of the effects of Ashwagandha on stress, inflammation, and immune modulation. Participants will take the liquid extract in cow's milk twice a day for five days. The results of initial, one-day, and final blood draws will be compared to determine participant's beginning and ending levels of cortisol, inflammatory cytokines, and immune-cell activation (CD4 T-cells, CD8 T-cells, B cells and natural killer cells). Measurements will be completed using flow cytometry and ELISA assay. The purpose of this study is to determine which effects of Ashwagandha are most suitable for further investigation.
Due to the increased use of alternative medicine, supplements and herbs are consumed more
frequently in the treatment of common ailments. This pilot study investigates the immune,
anti-inflammatory and anti-stress effects of Ashwagandha in human subjects.
Liquid extract of the herb will be taken followed by milk; this mode of administration will
be used as it approximates the traditional administration as well as making self
administration easier for participants. Extract will be taken in 3 milliliter quantities 2
times per day, (morning and evening), for five days. Total dosage of 6 milliliters will
approximate the higher end of the traditional daily dosage of 6 grams daily of powdered
root.
Flow of visit:
25 participants will arrive at the research lab and after being consented, filling out
health histories and two stress questionnaires, (POMS and STAI Self-Evaluation), average
milk intake questionnaire. The 25 participants will receive blood draws. They will then be
administered the herb extract, milk and instructions for taking them.
Subjects will return to the research institute after 24 hours for a second blood draw and
then after 5 days for a final blood draw and two more stress questionnaires, (POMS and STAI
Self-Evaluation).
Once the blood samples are drawn, they will be refrigerated and processed within 24 hours at
the NCNM laboratory. Initially they will be centrifuged to separate the white from the red
blood cells using Ficoll separating tubes. Then the white blood cells will be stained using
CD69 marker (Cytokine Detection type 69) which assesses cell-surface phenotypic markers in
combination with intracellular cytokines, measuring response to activation. It is especially
effective for rare-event, antigen-specific events, such as the administration of a specific
immune-stimulating herbal tincture. We will also stain with other similar florescent CD
markers specific for CD4 T-cells, CD8 T-cells, B-cells, NK cells, and macrophages. These
markers will be analyzed using a FACScan flow cytometer, which will count the number of
cells that have been activated in each subtype of the immune cell and overall action. Blood
will also be analyzed for cortisol levels and inflammatory cytokines, (IL-1, IL-6 and
TNF-alpha) using the ELISA assay procedure.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|